ID   NAPEP_HUMAN             Reviewed;         393 AA.
AC   Q6IQ20; Q5CZ87; Q769K1;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 2.
DT   22-JUL-2015, entry version 99.
DE   RecName: Full=N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D;
DE            Short=N-acyl phosphatidylethanolamine phospholipase D;
DE            Short=NAPE-PLD;
DE            Short=NAPE-hydrolyzing phospholipase D;
DE            EC=3.1.4.54;
GN   Name=NAPEPLD; Synonyms=C7orf18;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   PubMed=14634025; DOI=10.1074/jbc.M306642200;
RA   Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N.;
RT   "Molecular characterization of a phospholipase D generating anandamide
RT   and its congeners.";
RL   J. Biol. Chem. 279:5298-5305(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=15820312; DOI=10.1016/j.ygeno.2005.01.013;
RA   Curtiss N.P., Bonifas J.M., Lauchle J.O., Balkman J.D., Kratz C.P.,
RA   Emerling B.M., Green E.D., Le Beau M.M., Shannon K.M.;
RT   "Isolation and analysis of candidate myeloid tumor suppressor genes
RT   from a commonly deleted segment of 7q22.";
RL   Genomics 85:600-607(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-389.
RC   TISSUE=Colon carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-389.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-389.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF SER-152; LEU-207; HIS-380 AND
RP   ASP-389.
RX   PubMed=16527816; DOI=10.1074/jbc.M512359200;
RA   Wang J., Okamoto Y., Morishita J., Tsuboi K., Miyatake A., Ueda N.;
RT   "Functional analysis of the purified anandamide-generating
RT   phospholipase D as a member of the metallo-beta-lactamase family.";
RL   J. Biol. Chem. 281:12325-12335(2006).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Hydrolyzes N-acyl-phosphatidylethanolamines (NAPEs) to
CC       produce N-acylethanolamines (NAEs) and phosphatidic acid.
CC       Responsible for the generation of anandamide (N-
CC       arachidonoylethanolamine), the ligand of cannabinoid and vanilloid
CC       receptors (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: An N-acylphosphatidylethanolamine + H(2)O = an
CC       N-acylethanolamine + a 1,2-diacylglycerol 3-phosphate.
CC       {ECO:0000269|PubMed:14634025, ECO:0000269|PubMed:16527816}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 or 2 zinc ions per subunit. {ECO:0000250};
CC   -!- ENZYME REGULATION: Activity is stimulated by divalent cations.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the NAPE-PLD family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=N-acyl
CC       phosphatidylethanolamine-specific phospholipase D entry;
CC       URL="http://en.wikipedia.org/wiki/N-acyl_phosphatidylethanolamine-specific_phospholipase_D";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY357337; AAR13673.1; -; mRNA.
DR   EMBL; AB112352; BAD02399.1; -; mRNA.
DR   EMBL; CR936639; CAI56779.1; -; mRNA.
DR   EMBL; CH471070; EAW83314.1; -; Genomic_DNA.
DR   EMBL; BC071604; AAH71604.1; -; mRNA.
DR   CCDS; CCDS5729.1; -.
DR   RefSeq; NP_001116310.1; NM_001122838.1.
DR   RefSeq; NP_945341.3; NM_198990.4.
DR   RefSeq; XP_005250271.2; XM_005250214.3.
DR   RefSeq; XP_005250272.1; XM_005250215.1.
DR   RefSeq; XP_005250275.1; XM_005250218.1.
DR   RefSeq; XP_006725115.2; XM_006725052.2.
DR   RefSeq; XP_006725116.2; XM_006725053.2.
DR   RefSeq; XP_006725117.1; XM_006725054.1.
DR   RefSeq; XP_006725119.1; XM_006725056.1.
DR   RefSeq; XP_011514235.1; XM_011515933.1.
DR   UniGene; Hs.324271; -.
DR   ProteinModelPortal; Q6IQ20; -.
DR   BioGrid; 128793; 1.
DR   STRING; 9606.ENSP00000340093; -.
DR   PhosphoSite; Q6IQ20; -.
DR   BioMuta; NAPEPLD; -.
DR   DMDM; 167016292; -.
DR   MaxQB; Q6IQ20; -.
DR   PaxDb; Q6IQ20; -.
DR   PeptideAtlas; Q6IQ20; -.
DR   PRIDE; Q6IQ20; -.
DR   DNASU; 222236; -.
DR   Ensembl; ENST00000341533; ENSP00000340093; ENSG00000161048.
DR   Ensembl; ENST00000417955; ENSP00000407112; ENSG00000161048.
DR   Ensembl; ENST00000422589; ENSP00000412376; ENSG00000161048.
DR   Ensembl; ENST00000427257; ENSP00000392775; ENSG00000161048.
DR   Ensembl; ENST00000465647; ENSP00000419188; ENSG00000161048.
DR   Ensembl; ENST00000611100; ENSP00000482162; ENSG00000275723.
DR   Ensembl; ENST00000622712; ENSP00000481285; ENSG00000275723.
DR   GeneID; 222236; -.
DR   KEGG; hsa:222236; -.
DR   UCSC; uc003vbc.2; human.
DR   CTD; 222236; -.
DR   GeneCards; GC07M102742; -.
DR   HGNC; HGNC:21683; NAPEPLD.
DR   HPA; HPA019832; -.
DR   HPA; HPA024338; -.
DR   MIM; 612334; gene.
DR   neXtProt; NX_Q6IQ20; -.
DR   PharmGKB; PA162396960; -.
DR   eggNOG; COG2220; -.
DR   GeneTree; ENSGT00390000017990; -.
DR   HOGENOM; HOG000267495; -.
DR   HOVERGEN; HBG054649; -.
DR   InParanoid; Q6IQ20; -.
DR   KO; K13985; -.
DR   OMA; WSVLGPW; -.
DR   OrthoDB; EOG7Z95MB; -.
DR   PhylomeDB; Q6IQ20; -.
DR   TreeFam; TF313520; -.
DR   BioCyc; MetaCyc:ENSG00000161048-MONOMER; -.
DR   BRENDA; 3.1.4.54; 2681.
DR   Reactome; REACT_160194; Biosynthesis of A2E, implicated in retinal degradation.
DR   ChiTaRS; NAPEPLD; human.
DR   GenomeRNAi; 222236; -.
DR   NextBio; 91585; -.
DR   PRO; PR:Q6IQ20; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; Q6IQ20; -.
DR   CleanEx; HS_NAPEPLD; -.
DR   ExpressionAtlas; Q6IQ20; baseline and differential.
DR   Genevisible; Q6IQ20; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0042622; C:photoreceptor outer segment membrane; TAS:Reactome.
DR   GO; GO:0070290; F:N-acylphosphatidylethanolamine-specific phospholipase D activity; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   Gene3D; 3.60.15.10; -; 1.
DR   InterPro; IPR001279; Beta-lactamas-like.
DR   InterPro; IPR024884; NAPE-PLD.
DR   PIRSF; PIRSF038896; NAPE-PLD; 1.
DR   SUPFAM; SSF56281; SSF56281; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Membrane; Metal-binding; Phospholipid degradation;
KW   Phospholipid metabolism; Polymorphism; Reference proteome; Zinc.
FT   CHAIN         1    393       N-acyl-phosphatidylethanolamine-
FT                                hydrolyzing phospholipase D.
FT                                /FTId=PRO_0000318159.
FT   METAL       185    185       Zinc 1. {ECO:0000255}.
FT   METAL       187    187       Zinc 1. {ECO:0000255}.
FT   METAL       189    189       Zinc 2. {ECO:0000255}.
FT   METAL       190    190       Zinc 2. {ECO:0000255}.
FT   METAL       253    253       Zinc 1. {ECO:0000255}.
FT   METAL       343    343       Zinc 2. {ECO:0000255}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:22814378}.
FT   VARIANT     152    152       S -> A (in dbSNP:rs12540583).
FT                                /FTId=VAR_038695.
FT   VARIANT     389    389       D -> N (in dbSNP:rs3181009).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038694.
FT   MUTAGEN     152    152       S->A: Almost no change in activity.
FT                                {ECO:0000269|PubMed:16527816}.
FT   MUTAGEN     207    207       L->F: Loss of activity.
FT                                {ECO:0000269|PubMed:16527816}.
FT   MUTAGEN     380    380       H->R: Loss of activity.
FT                                {ECO:0000269|PubMed:16527816}.
FT   MUTAGEN     389    389       D->N: Almost no change in activity.
FT                                {ECO:0000269|PubMed:16527816}.
FT   CONFLICT    281    281       Missing (in Ref. 3; CAI56779).
FT                                {ECO:0000305}.
FT   CONFLICT    371    371       N -> Y (in Ref. 3; CAI56779).
FT                                {ECO:0000305}.
SQ   SEQUENCE   393 AA;  45596 MW;  5CE3114CC557B698 CRC64;
     MDENESNQSL MTSSQYPKEA VRKRQNSARN SGASDSSRFS RKSFKLDYRL EEDVTKSKKG
     KDGRFVNPWP TWKNPSIPNV LRWLIMEKDH SSVPSSKEEL DKELPVLKPY FITNPEEAGV
     REAGLRVTWL GHATVMVEMD ELIFLTDPIF SSRASPSQYM GPKRFRRSPC TISELPPIDA
     VLISHNHYDH LDYNSVIALN ERFGNELRWF VPLGLLDWMQ KCGCENVIEL DWWEENCVPG
     HDKVTFVFTP SQHWCKRTLM DDNKVLWGSW SVLGPWNRFF FAGDTGYCPA FEEIGKRFGP
     FDLAAIPIGA YEPRWFMKYQ HVDPEEAVRI HTDVQTKKSM AIHWGTFALA NEHYLEPPVK
     LNEALERYGL NAEDFFVLKH GESRYLNNDD ENF
//
